Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

528.500
0.000
Volume:303.90K
Turnover:160.36M
Market Cap:126.31B
PE:-274.18
High:537.500
Open:519.000
Low:519.000
Close:528.500
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.51
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.928
ROE:-9.34%
ROA:-5.11%
PB:22.31
PE(LYR):-274.18
PS:52.76

Loading ...

Kelun-biotech Names Zhou Zejian Sole Company Secretary After Chung Ming Fai Resignation

Reuters
·
Jul 07

Movement Alert|Kelun-Biotech Declines 3.06% in Regular Trading, Trading at HK$506.0

Market Focus
·
Jul 07

Movement Alert|Kelun-Biotech Rises 3.31% in Regular Trading, Multiple Brokerages Maintain Buy Ratings Amid ASCO Data Momentum

Market Focus
·
Jul 06

Movement Alert|Kelun-Biotech Rises 4.79% in Regular Trading, ASCO Phase III Data and Multiple Broker Upgrades Continue to Drive Momentum

Market Focus
·
Jul 03

Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap On New Cancer Cell Research?

Simply Wall St.
·
Jul 03

Market Analysis: Meta's AI Compute Sale Not a Bearish Signal; Healthcare Stocks Surge on Multiple Catalysts

Stock News
·
Jul 02

Movement Alert|Kelun-Biotech Rises 8.39% in Regular Trading, ASCO Phase III Data Continues to Catalyze Amid Biotech Sector Rally

Market Focus
·
Jul 02

Sichuan Kelun-Biotech Subscribes to Wealth Management Products

MT Newswires Live
·
Jul 01

SKB BIO Places Additional RMB600 Million in Principal-Guaranteed Structured Deposits; Wealth-Management Exposure Rises to RMB1.49 Billion

Bulletin Express
·
Jun 30

SKB BIO Allocates 600 Million Yuan for Structured Deposit Investments

Stock News
·
Jun 30

Sichuan Kelun-biotech Biopharmaceutical Co - Subscribes for Czb Structured Deposit V of Rmb200 Mln on June 30, 2026

THOMSON REUTERS
·
Jun 30

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 4.04% in Regular Trading, Multiple Brokerages Upgrade Ratings Following ASCO Phase III Data

Market Focus
·
Jun 30

Asian Market's Hidden Gems: 3 Stocks That Might Be Trading Below Fair Value

Simply Wall St.
·
Jun 30

Kelun-Biotech AGM Clears All 2025 Financials, Re-appoints KPMG and Renews Capital Mandates

Bulletin Express
·
Jun 29

Movement Alert|Kelun-Biotech Rises 7.18% in Regular Trading, ASCO Landmark Data Continues to Drive Momentum Alongside Sector Rally

Market Focus
·
Jun 29

Movement Alert|Kelun-Biotech Falls 3.08% in Regular Trading, Trading at 411.4 HKD

Market Focus
·
Jun 25

Movement Alert|Kelun-Biotech Rises 7.44% in Regular Trading, ASCO Phase III Lung Cancer Data Catalyzes Overseas Commercialization Expectations

Market Focus
·
Jun 24

SKB BIO Shares Surge Over 6% on Key ASCO Lung Cancer Data, sac-TMT Nears Global Commercialization

Stock News
·
Jun 24

Movement Alert|Kelun-Biotech Rises 3.16% in Regular Trading, Biotech Sector Broadly Rallies Amid Positive Analyst Coverage

Market Focus
·
Jun 23

Kelun-Biotech says Phase III trial tests sac-TMT plus osimertinib in first-line EGFR-mutant NSCLC

Reuters
·
Jun 22